218 related articles for article (PubMed ID: 28387573)
21. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Martin-Castillo B; Joven J; Menendez JA
Cell Cycle; 2010 Nov; 9(22):4461-8. PubMed ID: 21088486
[TBL] [Abstract][Full Text] [Related]
22. Metformin targets histone acetylation in cancer-prone epithelial cells.
Cuyàs E; Fernández-Arroyo S; Joven J; Menendez JA
Cell Cycle; 2016 Dec; 15(24):3355-3361. PubMed ID: 27792453
[TBL] [Abstract][Full Text] [Related]
23. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system.
Wang J; Chen TY; Qin S; Duan Y; Wang G
Med Hypotheses; 2013 Nov; 81(5):805-6. PubMed ID: 24074896
[TBL] [Abstract][Full Text] [Related]
25. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
[TBL] [Abstract][Full Text] [Related]
26. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
[TBL] [Abstract][Full Text] [Related]
28. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.
Barbieri F; Thellung S; Ratto A; Carra E; Marini V; Fucile C; Bajetto A; Pattarozzi A; Würth R; Gatti M; Campanella C; Vito G; Mattioli F; Pagano A; Daga A; Ferrari A; Florio T
BMC Cancer; 2015 Apr; 15():228. PubMed ID: 25884842
[TBL] [Abstract][Full Text] [Related]
30. RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.
Ciscar M; Trinidad EM; Perez-Chacon G; Alsaleem M; Jimenez M; Jimenez-Santos MJ; Perez-Montoyo H; Sanz-Moreno A; Vethencourt A; Toss M; Petit A; Soler-Monso MT; Lopez V; Gomez-Miragaya J; Gomez-Aleza C; Dobrolecki LE; Lewis MT; Bruna A; Mouron S; Quintela-Fandino M; Al-Shahrour F; Martinez-Aranda A; Sierra A; Green AR; Rakha E; Gonzalez-Suarez E
EMBO Mol Med; 2023 Apr; 15(4):e16715. PubMed ID: 36880458
[TBL] [Abstract][Full Text] [Related]
31. RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation.
Yoldi G; Pellegrini P; Trinidad EM; Cordero A; Gomez-Miragaya J; Serra-Musach J; Dougall WC; Muñoz P; Pujana MA; Planelles L; González-Suárez E
Cancer Res; 2016 Oct; 76(19):5857-5869. PubMed ID: 27480274
[TBL] [Abstract][Full Text] [Related]
32. PYK2 promotes HER2-positive breast cancer invasion.
Al-Juboori SI; Vadakekolathu J; Idri S; Wagner S; Zafeiris D; Pearson JR; Almshayakhchi R; Caraglia M; Desiderio V; Miles AK; Boocock DJ; Ball GR; Regad T
J Exp Clin Cancer Res; 2019 May; 38(1):210. PubMed ID: 31118051
[TBL] [Abstract][Full Text] [Related]
33. BRCA1 Attenuates Progesterone Effects on Proliferation and NFκB Activation in Normal Human Mammary Epithelial Cells.
Hilton HN; Patterson McDonald LJ; Santucci N; van der Bent FR; Silvestri A; Graham JD; Clarke CL
J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):257-270. PubMed ID: 31104199
[TBL] [Abstract][Full Text] [Related]
34. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats.
Mai QG; Zhang ZM; Xu S; Lu M; Zhou RP; Zhao L; Jia CH; Wen ZH; Jin DD; Bai XC
J Cell Biochem; 2011 Oct; 112(10):2902-9. PubMed ID: 21618594
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of the metabolic modulator Metformin on osteosarcoma cancer stem-like cells.
Paiva-Oliveira DI; Martins-Neves SR; Abrunhosa AJ; Fontes-Ribeiro C; Gomes CMF
Cancer Chemother Pharmacol; 2018 Jan; 81(1):49-63. PubMed ID: 29086064
[TBL] [Abstract][Full Text] [Related]
36. Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile.
Oliveras-Ferraros C; Vazquez-Martin A; Cuyàs E; Corominas-Faja B; Rodríguez-Gallego E; Fernández-Arroyo S; Martin-Castillo B; Joven J; Menendez JA
Cell Cycle; 2014; 13(7):1132-44. PubMed ID: 24553122
[TBL] [Abstract][Full Text] [Related]
37. Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Odén L; Akbari M; Zaman T; Singer CF; Sun P; Narod SA; Salmena L; Kotsopoulos J
Oncotarget; 2016 Dec; 7(52):86687-86694. PubMed ID: 27893411
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells.
Zhang X; Wang Y; Chiang HC; Hsieh YP; Lu C; Park BH; Jatoi I; Jin VX; Hu Y; Li R
Breast Cancer Res; 2019 Apr; 21(1):51. PubMed ID: 30995943
[TBL] [Abstract][Full Text] [Related]
39. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.
Zheng Y; Chow SO; Boernert K; Basel D; Mikuscheva A; Kim S; Fong-Yee C; Trivedi T; Buttgereit F; Sutherland RL; Dunstan CR; Zhou H; Seibel MJ
J Bone Miner Res; 2014 Sep; 29(9):1938-49. PubMed ID: 24676805
[TBL] [Abstract][Full Text] [Related]
40. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
